GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mymetics Corp (OTCPK:MYMX) » Definitions » Price-to-Owner-Earnings

Mymetics (Mymetics) Price-to-Owner-Earnings : (As of May. 27, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Mymetics Price-to-Owner-Earnings?

As of today (2024-05-27), Mymetics's share price is $0.01. Mymetics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Mymetics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Mymetics was 47.83. The lowest was 0.79. And the median was 3.18.


MYMX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.14
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-27), Mymetics's share price is $0.01. Mymetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-96.95. Therefore, Mymetics's PE Ratio for today is At Loss.

As of today (2024-05-27), Mymetics's share price is $0.01. Mymetics's EPS without NRI for the trailing twelve months (TTM) ended in was $-49.37. Therefore, Mymetics's PE Ratio without NRI for today is At Loss.

During the past 13 years, Mymetics's highest PE Ratio without NRI was 15.69. The lowest was 0.00. And the median was 13.45.


Mymetics Price-to-Owner-Earnings Historical Data

The historical data trend for Mymetics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mymetics Price-to-Owner-Earnings Chart

Mymetics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mymetics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mymetics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Mymetics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mymetics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mymetics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Mymetics's Price-to-Owner-Earnings falls into.



Mymetics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Mymetics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.01/-59.46
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mymetics  (OTCPK:MYMX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Mymetics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Mymetics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Mymetics (Mymetics) Business Description

Traded in Other Exchanges
N/A
Address
c/o Mymetics SA, Route de la Corniche 4, Biopole Center, Epalinges, CHE, CH-1066
Mymetics Corp is a vaccine company and is focused on the research and development of next-generation vaccines for infectious and life-disabling diseases. Its vaccine candidates in the pipeline include HIV-1/AIDS, malaria, and Covid-19, and intranasal influenza, RSV, Chikungunyaand HSV vaccine candidate programs.
Executives
Marcel B. Ruegg director C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Kempers Ronald Hugo Gerard officer: President, CEO, CFO ES GRANDS CHAMPS 12, DULLY V8 1195
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Grant Pickering director, officer: President and CEO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Ulrich Burkhard director C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Jacques Francois Martin officer: CEO 40 QUAI FULCHIRON, LYON I0 69005
Antonius Johannes Stegmann officer: CSO KONINGIN EMMAPLANTSOEN 6, RIJNSBURG P7 2231TZ
Ernest M Stern director 815 CONNECTICUT AVE, NW, SUITE 500, SEYFARTH SHAW LLP, WASHINGTON DC 20006
Thomas Staehelin director POSTFACH 2879, FROMER, SCHULTHEISS & STAEHELIN, BASEL V8 CH-4002
Sylvain Fleury officer: CSO CHEMIN DE VERDONNET 9, LAUSANNE V8 1010
Round Enterprises, Ltd. 10 percent owner C/O BACHMANN TRUST COMPANY LIMITED, FRANCES HOUSE, SIR WILLIAM PLACE, ST. PETER PORT X0 GY1 4EA
Mfc Bancorp Ltd 10 percent owner ROOM 2103 SHANGHAI MART TOWER, 2299 YAN AN ROAD WEST, CHANGNING DISTRICT, SHANGHAI F4 200336
Christian Rochet director, officer: CEO 14, RUE DE LA COLOMBIERE, NYON V8 1260
Robert Zimmer director, officer: vp corp development
Ernst Lubke director, officer: CFO 39, ROUTE D'ARZIER, ARZIER V8 CH-1273